HF Advisory Group LLC Has $317,000 Stake in GSK plc (NYSE:GSK)

HF Advisory Group LLC reduced its holdings in GSK plc (NYSE:GSK) by 8.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 7,753 shares of the pharmaceutical company’s stock after selling 717 shares during the period. HF Advisory Group LLC’s holdings in GSK were worth $317,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GSK. Cohen Investment Advisors LLC acquired a new stake in shares of GSK in the 2nd quarter valued at approximately $349,000. Van ECK Associates Corp increased its stake in GSK by 8.4% in the third quarter. Van ECK Associates Corp now owns 736,510 shares of the pharmaceutical company’s stock valued at $27,973,000 after purchasing an additional 56,843 shares in the last quarter. Blair William & Co. IL raised its holdings in GSK by 14.9% in the first quarter. Blair William & Co. IL now owns 23,493 shares of the pharmaceutical company’s stock worth $1,007,000 after purchasing an additional 3,044 shares during the period. SG Americas Securities LLC boosted its position in shares of GSK by 448.7% during the first quarter. SG Americas Securities LLC now owns 17,690 shares of the pharmaceutical company’s stock worth $758,000 after purchasing an additional 14,466 shares in the last quarter. Finally, Royal Fund Management LLC grew its holdings in shares of GSK by 87.0% in the 3rd quarter. Royal Fund Management LLC now owns 42,456 shares of the pharmaceutical company’s stock valued at $1,737,000 after buying an additional 19,758 shares during the period. 15.74% of the stock is owned by institutional investors.

Insider Buying and Selling at GSK

In other news, major shareholder Plc Gsk purchased 2,791,930 shares of GSK stock in a transaction on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

GSK Price Performance

GSK stock opened at $35.90 on Thursday. The stock has a 50-day moving average price of $40.25 and a two-hundred day moving average price of $40.97. GSK plc has a 1 year low of $33.89 and a 1 year high of $45.92. The stock has a market cap of $74.39 billion, a PE ratio of 23.31, a price-to-earnings-growth ratio of 1.42 and a beta of 0.66. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a yield of 4.38%. The ex-dividend date of this dividend is Friday, November 15th. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 100.00%.

Analysts Set New Price Targets

Several analysts recently commented on GSK shares. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.